MX2016007333A - Clasificacion de cancer de prostata. - Google Patents
Clasificacion de cancer de prostata.Info
- Publication number
- MX2016007333A MX2016007333A MX2016007333A MX2016007333A MX2016007333A MX 2016007333 A MX2016007333 A MX 2016007333A MX 2016007333 A MX2016007333 A MX 2016007333A MX 2016007333 A MX2016007333 A MX 2016007333A MX 2016007333 A MX2016007333 A MX 2016007333A
- Authority
- MX
- Mexico
- Prior art keywords
- nfil3
- prostate cancer
- methods
- individual
- cancer classification
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G01N33/57555—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322034.8A GB201322034D0 (en) | 2013-12-12 | 2013-12-12 | Prostate cancer classification |
| PCT/GB2014/053694 WO2015087088A2 (en) | 2013-12-12 | 2014-12-12 | Prostate cancer classification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007333A true MX2016007333A (es) | 2016-10-13 |
Family
ID=50030858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007333A MX2016007333A (es) | 2013-12-12 | 2014-12-12 | Clasificacion de cancer de prostata. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10196697B2 (enExample) |
| EP (1) | EP3080293B1 (enExample) |
| JP (1) | JP2017507320A (enExample) |
| KR (1) | KR20160098351A (enExample) |
| CN (1) | CN105940117A (enExample) |
| AU (1) | AU2014363173A1 (enExample) |
| BR (1) | BR112016013182A2 (enExample) |
| CA (1) | CA2932553A1 (enExample) |
| GB (1) | GB201322034D0 (enExample) |
| IL (1) | IL246067A0 (enExample) |
| MX (1) | MX2016007333A (enExample) |
| SG (1) | SG11201604508PA (enExample) |
| WO (1) | WO2015087088A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11035005B2 (en) | 2012-08-16 | 2021-06-15 | Decipher Biosciences, Inc. | Cancer diagnostics using biomarkers |
| CA2996426A1 (en) * | 2015-10-05 | 2017-04-13 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
| US20190024184A1 (en) * | 2015-12-23 | 2019-01-24 | Fred Hutchinson Cancer Research Center | Distinguishing metastatic-lethal prostate cancer from indolent prostate cancer using methylation status of epigenetic markers |
| CA3011106A1 (en) * | 2016-01-20 | 2017-07-27 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for screening and identifying clinically aggressive prostate cancer |
| WO2018039490A1 (en) | 2016-08-24 | 2018-03-01 | Genomedx Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| EP3593140A4 (en) * | 2017-03-09 | 2021-01-06 | Decipher Biosciences, Inc. | SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY |
| US12497660B2 (en) | 2017-08-04 | 2025-12-16 | Veracyte SD, Inc. | Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy |
| WO2019195658A1 (en) * | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| CN109295208A (zh) * | 2018-10-26 | 2019-02-01 | 德阳市人民医院 | Pi15作为骨关节炎标志物的应用 |
| AU2020215177A1 (en) * | 2019-01-30 | 2021-08-12 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| GB201917428D0 (en) * | 2019-11-29 | 2020-01-15 | Univ Newcastle | Prostate cancer diagnostic |
| CN111518908B (zh) * | 2020-05-18 | 2023-10-17 | 奥尔文泰生物科技(杭州)有限公司 | 尿液前列腺癌标志物组合及其在制备精准诊断试剂中的用途 |
| EP3960878A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Selection of a dose for radiotherapy of a prostate cancer subject |
| EP3960876A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Prediction of a response of a prostate cancer subject to radiotherapy based on pde4d7 correlated genes |
| EP3960877A1 (en) * | 2020-08-31 | 2022-03-02 | Koninklijke Philips N.V. | Prediction of a response of a prostate cancer subject to therapy or personalization of therapy of a prostate cancer subject |
| JP7477872B2 (ja) * | 2020-09-30 | 2024-05-07 | 国立大学法人大阪大学 | 癌に関連する新規バイオマーカー |
| CN113234820A (zh) * | 2021-04-29 | 2021-08-10 | 北京艾克伦医疗科技有限公司 | 鉴定前列腺癌状态的方法和试剂盒 |
| WO2023135485A1 (en) * | 2022-01-13 | 2023-07-20 | Oslo Universitetssykehus Hf | Prostate cancer markers and uses thereof |
| EP4253567A1 (en) | 2022-03-31 | 2023-10-04 | OncoAssure Limited | A method of predicting risk of an aggressive or recurrent cancer |
| WO2023220314A1 (en) * | 2022-05-12 | 2023-11-16 | Veracyte SD, Inc. | Prognosis and treatment of molecular subtypes of prostate cancer |
| CN116891523B (zh) * | 2023-05-24 | 2024-05-17 | 深圳晶蛋生物医药科技有限公司 | 一种trpm3截短体、包含其的细胞系及其用途 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2774121B2 (ja) | 1987-07-31 | 1998-07-09 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 標的ポリヌクレオチド配列の選択的増幅 |
| ZA899593B (en) | 1988-12-16 | 1990-09-26 | Siska Diagnostics Inc | Self-sustained,sequence replication system |
| US5437975A (en) | 1991-02-25 | 1995-08-01 | California Institute Of Biological Research | Consensus sequence primed polymerase chain reaction method for fingerprinting genomes |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US7220557B2 (en) | 1997-04-24 | 2007-05-22 | Human Genome Sciences, Inc. | METH1 polynucleotides |
| US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| AU2002214576A1 (en) | 2000-10-13 | 2002-04-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Genes related to development of refractory prostate cancer |
| PL365605A1 (en) | 2000-11-28 | 2005-01-10 | Wyeth | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| WO2003009814A2 (en) | 2001-07-25 | 2003-02-06 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20040029151A1 (en) | 2002-04-09 | 2004-02-12 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
| US20050032065A1 (en) | 2002-06-24 | 2005-02-10 | Afar Daniel E. H. | Methods of prognosis of prostate cancer |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| US20050259483A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
| WO2004067726A2 (en) | 2003-01-29 | 2004-08-12 | Keck Graduate Institute | Isothermal reactions for the amplification of oligonucleotides |
| US20040223970A1 (en) | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
| US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| WO2005083118A2 (en) * | 2004-02-27 | 2005-09-09 | Oncotherapy Science, Inc. | Pin-prc transition genes |
| US7666595B2 (en) * | 2005-02-25 | 2010-02-23 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
| WO2006110264A2 (en) | 2005-03-16 | 2006-10-19 | Sidney Kimmel Cancer Center | Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures |
| WO2006113529A2 (en) | 2005-04-15 | 2006-10-26 | Becton, Dickinson And Company | Diagnosis of sepsis |
| EP1717320A1 (en) | 2005-04-26 | 2006-11-02 | TopoTarget Germany AG | Identification of human gene sequences of cancer antigens expressed in metastatic carcinoma and involved in metastasis formation, and their use in cancer diagnosis, prognosis and therapy |
| WO2007030919A1 (en) | 2005-09-14 | 2007-03-22 | National Research Council Of Canada | Molecular method for diagnosis of prostate cancer |
| US20070059753A1 (en) | 2005-09-15 | 2007-03-15 | Tatiana Vener | Detecting gene methylation |
| CA2629008A1 (en) | 2005-11-08 | 2007-09-13 | Euclid Diagnostics Llc | Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer |
| WO2008067065A2 (en) | 2006-10-19 | 2008-06-05 | Shiv Srivastava | Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers |
| US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| WO2008086478A2 (en) | 2007-01-10 | 2008-07-17 | Henry Ford Health System | Methods and compositions for identification of prostate cancer markers |
| AU2007350331A1 (en) | 2007-03-30 | 2008-10-09 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for identification, monitoring, and treatment of prostate cancer |
| EP2190478B1 (en) | 2007-08-24 | 2016-03-23 | Oncotherapy Science, Inc. | Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| WO2009151503A2 (en) | 2008-04-10 | 2009-12-17 | University Of Florida Research Foundation, Inc. | Compositions and methods for the treatment of a neoplasia |
| US20110159498A1 (en) | 2008-04-11 | 2011-06-30 | China Synthetic Rubber Corporation | Methods, agents and kits for the detection of cancer |
| US20110136683A1 (en) | 2008-05-28 | 2011-06-09 | Genomedx Biosciences, Inc. | Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer |
| US20090298082A1 (en) | 2008-05-30 | 2009-12-03 | Klee George G | Biomarker panels for predicting prostate cancer outcomes |
| US20120009581A1 (en) | 2008-07-08 | 2012-01-12 | Bankaitis-Davis Danute M | Gene Expression Profiling for Predicting the Survivability of Prostate Cancer Subjects |
| CN102159727A (zh) | 2008-07-16 | 2011-08-17 | 达纳-法伯癌症研究院有限公司 | 与前列腺癌有关的信号和胆碱磷酸决定子以及它们的使用方法 |
| US20100055705A1 (en) | 2008-08-29 | 2010-03-04 | Wilson Gerald M | Compositions and methods for diagnosing and treating cancer |
| CA2742324A1 (en) | 2008-10-30 | 2010-06-03 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Methods for assessing rna patterns |
| EP2370813A4 (en) | 2008-12-04 | 2012-05-23 | Univ California | MATERIALS AND METHODS FOR DIAGNOSIS AND PRESENTATION OF PROSTATE CANCER |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| CN102439176B (zh) | 2009-05-12 | 2018-11-23 | 皇家飞利浦电子股份有限公司 | 用作恶性的、激素-敏感的前列腺癌的标志物的磷酸二酯酶4d7 |
| JP6148007B2 (ja) | 2009-05-12 | 2017-06-14 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ |
| ES2516866T3 (es) | 2009-06-04 | 2014-10-31 | Metanomics Health Gmbh | Medios y métodos para el diagnóstico de carcinomas de próstata |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| EP2309273B1 (en) | 2009-09-16 | 2016-05-18 | ZEILLINGER, Robert | Novel tumor marker determination |
| EP2692871A1 (en) | 2009-12-01 | 2014-02-05 | Compendia Bioscience, Inc. | Classification of cancers |
| WO2011094233A1 (en) | 2010-01-26 | 2011-08-04 | The Johns Hopkins University | Methods of disease classification or prognosis for prostate cancer based on expression of cancer/testis antigens |
| WO2011106709A2 (en) | 2010-02-26 | 2011-09-01 | Board Of Regents, The University Of Texas System | Epithelial biomarkers for cancer prognosis |
| BR112012022641A2 (pt) | 2010-03-11 | 2017-02-14 | Oncotherapy Science Inc | peptídeos hjurp e vacinas que incluem os mesmos |
| WO2011153287A2 (en) | 2010-06-01 | 2011-12-08 | Indiana University Research And Technology Corporation | Materials and methods for diagnosing and predicting the course of prostate cancer |
| CA2804391A1 (en) | 2010-07-07 | 2012-01-12 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| WO2012018609A2 (en) | 2010-07-26 | 2012-02-09 | The Johns Hopkins University | Mig6 and therapeutic efficacy |
| ES2925983T3 (es) | 2010-07-27 | 2022-10-20 | Genomic Health Inc | Método para usar la expresión génica para determinar el pronóstico del cáncer de próstata |
| WO2012030840A2 (en) | 2010-08-30 | 2012-03-08 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| EP2702177B1 (en) | 2011-04-28 | 2017-04-12 | New York University | Genomic signatures of metastasis in prostate cancer |
| AU2012275500A1 (en) | 2011-06-27 | 2014-01-16 | Dana-Farber Cancer Institute, Inc. | Signatures and determinants associated with prostate cancer progression and methods of use thereof |
| US20130079241A1 (en) * | 2011-09-15 | 2013-03-28 | Jianhua Luo | Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse |
| GB201206209D0 (en) | 2012-04-06 | 2012-05-23 | Univ Leuven Kath | Marker gene based diagnosis, staging and prognosis of prostate caner |
| ES2673960T3 (es) | 2011-12-22 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Métodos para modular la expresión de un transcrito-1 de adenocarcinoma en pulmón asociado a metástasis (MALAT-1) |
| DK3179393T3 (da) | 2012-01-31 | 2020-07-27 | Genomic Health Inc | Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft |
| TW201343920A (zh) | 2012-03-29 | 2013-11-01 | 財團法人國家衛生研究院 | 預測前列腺癌預後之分子標記、方法與套組 |
| BR102012007246A2 (pt) | 2012-03-30 | 2016-02-10 | Fundação Antonio Prudente | métodos para prognóstico e classificação de resultados de um evento |
| US20130288967A1 (en) | 2012-04-25 | 2013-10-31 | Euclid Diagnostics Llc | Materials and methods for cancer diagnosis by evaluation of the methylation status of cpg islands on chromosomes 6 and 8 |
| CN103146688B (zh) | 2012-09-12 | 2015-05-13 | 上海长海医院 | 长链非编码rna作为疾病诊断血液分子标志物的应用 |
-
2013
- 2013-12-12 GB GBGB1322034.8A patent/GB201322034D0/en not_active Ceased
-
2014
- 2014-12-12 KR KR1020167018629A patent/KR20160098351A/ko not_active Withdrawn
- 2014-12-12 CA CA2932553A patent/CA2932553A1/en not_active Abandoned
- 2014-12-12 SG SG11201604508PA patent/SG11201604508PA/en unknown
- 2014-12-12 AU AU2014363173A patent/AU2014363173A1/en not_active Abandoned
- 2014-12-12 MX MX2016007333A patent/MX2016007333A/es unknown
- 2014-12-12 BR BR112016013182A patent/BR112016013182A2/pt not_active Application Discontinuation
- 2014-12-12 CN CN201480074318.2A patent/CN105940117A/zh active Pending
- 2014-12-12 US US15/103,770 patent/US10196697B2/en not_active Expired - Fee Related
- 2014-12-12 JP JP2016538689A patent/JP2017507320A/ja active Pending
- 2014-12-12 WO PCT/GB2014/053694 patent/WO2015087088A2/en not_active Ceased
- 2014-12-12 EP EP14814697.0A patent/EP3080293B1/en active Active
-
2016
- 2016-06-06 IL IL246067A patent/IL246067A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160312294A1 (en) | 2016-10-27 |
| EP3080293A2 (en) | 2016-10-19 |
| CA2932553A1 (en) | 2015-06-18 |
| KR20160098351A (ko) | 2016-08-18 |
| US10196697B2 (en) | 2019-02-05 |
| CN105940117A (zh) | 2016-09-14 |
| GB201322034D0 (en) | 2014-01-29 |
| JP2017507320A (ja) | 2017-03-16 |
| WO2015087088A2 (en) | 2015-06-18 |
| AU2014363173A1 (en) | 2016-07-07 |
| IL246067A0 (en) | 2016-07-31 |
| SG11201604508PA (en) | 2016-07-28 |
| WO2015087088A3 (en) | 2015-09-17 |
| BR112016013182A2 (pt) | 2017-09-26 |
| EP3080293B1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016007333A (es) | Clasificacion de cancer de prostata. | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| BR112014007214A8 (pt) | Método para determinar a probabilidade de que um indivíduo tenha risco elevado de um evento cardiovascular, método para avaliação do risco de um evento cardiovascular futuro e método implementado por computador para avaliação do risco de um evento cardiovascular | |
| EA201691499A1 (ru) | Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям | |
| ES2721907T3 (es) | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal | |
| HK1223361A1 (zh) | 用於预测肠易激综合征诊断的途径特异性测定 | |
| BR112017012222A2 (pt) | métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit. | |
| EA201390762A1 (ru) | Новые биомаркеры для предсказания исхода противораковой иммунотерапии | |
| EA201791578A1 (ru) | Панель биомаркеров для обнаружения рака | |
| WO2016198833A3 (en) | Methods for analysing a urine sample | |
| UY36200A (es) | Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado | |
| HK1222888A1 (zh) | 预测在淋巴结阳性早期乳癌复发风险的方法 | |
| BR112016029562A2 (pt) | métodos para tratar, diagnosticar e prognosticar uma malignidade hematológica | |
| ES2721477T3 (es) | Materiales y métodos para evaluar la progresión del cáncer de próstata | |
| MX2015013993A (es) | Procedimientos y series para su uso en los mismos. | |
| Hongliang et al. | Correlation between expression of miR-155 in colon cancer and serum carcinoembryonic antigen level and its contribution to recurrence and metastasis forecast. | |
| SG11201811433TA (en) | Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method | |
| Song et al. | Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma. | |
| MX360225B (es) | Ensayos de receptores de esteroides para detectar celulas tumorales. | |
| Chang et al. | Hypothesis testing on the common location parameter of several shifted exponential distributions: A note | |
| XU et al. | Circulating and tumor miR-21 could predict irinotecan sensitivity in gastric cancer | |
| Zhang et al. | Detection of expression of microRNAs in serum of loco-regionally advanced nasopharyngeal carcinoma patients: A potential marker for prognosis prediction of nasopharyngeal carcinoma treated with concurrent chemoradiotherapy screening | |
| Li et al. | Serum miRNAs as new biomarkers for esophageal squamous cell carcinoma | |
| CHEN et al. | Expression of EIF5A2 in Esophageal Squamous Cell Carcinoma and Its Correlation with the Prognosis | |
| Yang et al. | The prognostic value of B7-H6 in esophageal squamous cell carcinoma |